COMBINATION THERAPY USING SUBSTITUTED PYRIMIDIN-4(3H)-ONES AND SOTORASIB

The present disclosure provides a method of treating cancer in a subject. The method including administering to the subject: a) a therapeutically effective amount of a compound of formula (I); and b) a therapeutically effective amount of sotorasib, wherein the compound of formula (I) is represented...

Full description

Saved in:
Bibliographic Details
Main Authors STICE, James, WADE, Anna, MEYERS, Brooke, SINKEVICIUS, Kerstin, SUN, Yuting, WOOD, Lauren, DAMBKOWSKI, Carl, LIM, Justin, WALLACE, Eli, VAN VEENHUYZEN, David, BELTRAN, Pedro, KOHL, Nancy
Format Patent
LanguageEnglish
Published 09.01.2025
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides a method of treating cancer in a subject. The method including administering to the subject: a) a therapeutically effective amount of a compound of formula (I); and b) a therapeutically effective amount of sotorasib, wherein the compound of formula (I) is represented by (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, conformational isomer, tautomer, or a combination thereof. In particular, the present disclosure provides a method of treating a solid tumor (e.g., an advanced or metastatic non-small cell lung cancer) with a therapeutically effective amount of a compound of formula (10b) (i.e., 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(Ra)-(2,3-dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one) in combination with sotorasib in a subject, wherein the subject has one or more mutations in KRAS, such as KRAS G12C.
Bibliography:Application Number: US202218696931